home > news

> News

> Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier

News

09/05/2025

Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier

Read the full article below.

Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier

Our news

News

21/02/2025
Interview of Hervé Affagard, President of EMIH
> READ

News

11/01/2023
Organic S. boulardii: A Probiotic Breakthrough by Lallemand
> READ

News

02/06/2025
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease
> READ

> See all news